NCT03603795 - Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy | Biotech Hunter

Enrollment

110

Participants

Timeline

Start Date

October 11, 2018

Primary Completion Date

June 15, 2022

Study Completion Date

July 30, 2026

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Eltrombopag

Eltrombopag concomitant with induction chemotherapy in patient with AML

DRUG

Placebo

Placebo concomitant with induction chemotherapy patients with AML

Trial Locations (15)

13000

Institut Paoli-Calmettes - Hématologie 2, Marseille

30029

CHU Caremeau, Nîmes

31059

Institut Universitaire du Cancer de Toulouse Oncopole - Service d'Hématologie, Toulouse

34295

Hôpital Saint-Eloi - Hématologie Clinique, Montpellier

35033

CHU Pontchaillou, Rennes

37044

Sponsor FILO, Tours

38043

CHU Grenoble - Hématologie Clinique, Grenoble

44093

CHU HOTEL DIEU - Hématologie Clinique, Nantes

49933

CHU ANGERS - Maladies du sang, Angers

54500

CHU de Brabois, Vandœuvre-lès-Nancy

63003

CHU Estaing, Clermont-Ferrand

64109

CH de la Côte Basque - Hématologie, Bayonne

67098

CHU Hautepierre - Hématologie, Strasbourg

68070

HOPITAL E. MULLER - Hématologie, Mulhouse

86000

CHU La Milétrie - Hématologie Clinique, Poitiers